ICU Medical (NSDQ:ICUI) ICU Medical today said it will acquire Pursuit Vascular for $75 million. Through the definitive agreement, ICU Medical will have additional earnout payment potentially due in 2021. “ICU Medical has always been deeply focused on improving patient safety and creating the best workflow for clinicians. The ClearGuard HD is natural extension of our […]
Pursuit Vascular expands in U.S., eyes Europe
Pursuit Vascular said yesterday that it expanded its domestic footprint and plans to apply for entrance to the European market next year. Maple Grove, Minn.-based Pursuit Vascular, which makes the ClearGuard HD antimicrobial caps for preventing central-line-associated bloodstream infections, said increased demand for the product prompted it to open new facilities in Dallas, Atlanta and Philadelphia. The […]
Motus GI taps Moran as CEO | Personnel Moves – September 25, 2018
Motus GI said today that it named Timothy Moran as its new chief executive officer, effective October 1, replacing former CEO Mark Pomeranz who will assume the role of president and COO. Moran has previously served ConvaTec‘s (LON:CTEC) Americas president and helped lead the company through its initial public offering in 2016. Prior to ConvaTec, Moran spent […]
Pursuit Vascular wins expanded indication for antimicrobial device
Pursuit Vascular (Maple Grove, Minn.) today announced that it has won FDA clearance for a broader indication of its ClearGuard HD antimicrobial caps. The new indication for the caps — used as an antimicrobial device for catheter-based dialysis patients — includes reduction in the incidence of central-line associated bloodstream infection in hemodialysis patients with central venous […]
Pursuit Vascular raises $2.1m
Pursuit Vascular has raised $2.1 million in a new round of debt financing, according to an SEC filing posted today. Maple Grove, Minn.-based Pursuit Vascular produces the ClearGueard HD end caps for hemodialysis catheters, designed to kill bacteria inside long-term hemodialysis catheters. The caps are designed with a chlorhexidine-coated rod that extends into the catheter […]
DreaMed inks licensing deal for artificial pancreas technology with Medtronic | Medtech funding for the week of April 6, 2015
Pursuit Vascular tracks down another $5m
The fundraising continues at Minnesota’s Pursuit Vascular, which has reeled in more than $5.1 million through a new equity offering.
Executives disclosed the new cash infusion in a recent regulatory filing, though specific investors are not mentioned.
Pursuit Vascular lands $1.6m for ClearGuard device
Pursuit Vascular said it raise approximately $1.6 million in a debt and securities offering to a group of 33 unnamed investors.
Based in Maple Grove, Minn., Pursuit markets a device called ClearGuard that’s designed to kill bacteria and fungi in hemodialysis catheters. The product, an antimicrobial fluid lock, received FDA approval in late 2013.
Pursuit Vascular nears $1.6M funding goal
Pursuit Vascular is close to reaching a $1.6 million funding goal, having raised $1.57 million, according to a regulatory filing.
Minneapolis-based Pursuit Vascular is devleoping technology for reducing catheter infections, including the ClearGuard platform that’s designed to cut infections associated with hemodialysis catheters.
GMI Ratings adds Boston Scientific to risky bet list | Wall Street Beat
A rating agency specializing in evaluating risky investments added Boston Scientific (NYSE:BSX) to its "Risk List," citing the ongoing fallout from its ill-starred Guidant buyout, its accounting and governance practices and how it pays its executives.
